Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab-Reference-Cited by-同舟云学术

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab

Published:2022-12 Issue:12 Volume:23 Page:e552-e561
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Malmberg Ruben,Zietse Michiel,Dumoulin Daphne W,Hendrikx Jeroen J M A,Aerts Joachim G J V,van der Veldt Astrid A M,Koch Birgit C P,Sleijfer Stefan,van Leeuwen Roelof W F

Publisher

Elsevier BV

Subject

Oncology

Reference60 articles.

1. Improving access to immunotherapy in low- and middle-income countries;Patel;Ann Oncol,2022

2. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer;Goldstein;J Natl Cancer Inst,2017

3. Fixed dosing of monoclonal antibodies in oncology;Hendrikx;Oncologist,2017

4. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors;Patnaik;Clin Cancer Res,2015

5. Evaluation of dosing strategy for pembrolizumab for oncology indications;Freshwater;J Immunother Cancer,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective;Lung Cancer;2024-10

3. Tumor‐associated exosomes in cancer progression and therapeutic targets;MedComm;2024-09

4. Could molecular farming be a game changing paradigm in the production of immune checkpoint inhibitors for cancer immunotherapy?;Vacunas;2024-08

5. The Triad of Sleep, Immunity, and Cancer: A Mediating Perspective;Cells;2024-07-24